Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms

Uzzan, Mathieu; Soudan, Damien; Peoc’h, Katell; Weiss, Emmanuel; Corcos, Olivier

doi:10.1016/j.dld.2020.06.042

Cited by 19 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with this, epithelial cell damage has been shown in both bat and human enteroids which developed progressive cytopathic effect after SARS-CoV-2 inoculation. 19 In addition, Uzzan et al, 40 assessed plasma concentrations of the amino acid citrulline, a surrogate marker of enterocyte mass and function. 41 Compared to COVID-19 patients without gastrointestinal symptoms, those with symptoms (ie, nausea, vomiting, and loss of appetite) had lower plasma citrulline levels and low plasma citrulline was inversely correlated with inflammatory markers, including C-reactive protein and ferritin.…”

Section: Epithelial Cell Damagementioning

confidence: 99%

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Marasco

Lenti

Cremon

et al. 2021

Neurogastroenterology Motil

View full text Add to dashboard Cite

Health Organization reported more than 32 million cases and 995 thousands deaths from 235 countries related to this pandemic. 2 The clinical course of SARS-CoV-2 infection can span a wide range from asymptomatic to a rapidly progressing and life-threatening disease, most commonly associated with a variety of symptoms, such as fever, cough, dyspnea, pneumonia, acute respiratory distress syndrome, systemic inflammatory response syndrome, and multiple

show abstract

Section: Epithelial Cell Damagementioning

confidence: 99%

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Marasco

Lenti

Cremon

et al. 2021

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…Several studies have evaluated biomarkers that can help predict severe complications in COVID-19 patients including but not limited to virus load [10], interleukin (IL)-6 [25], D-dimer [26], C-reactive protein (CRP) [27], lactate dehydrogenase (LDH) [27], ferritin [27], serum amyloid A (SAA) [28,29] as well as components of the complement pathways [30,31] and others [32] (Table 1). Interestingly, combining biomarkers can increase the predictive value for COVID-19 outcomes [20].…”

Section: Introductionmentioning

confidence: 99%

Circulating Calprotectin as a Biomarker of COVID-19 Severity

Mähler

Meroni

Infantino

et al. 2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although demographic and clinical parameters such as sex, age, comorbidities, genetic background and various biomarkers have been identified as risk factors, there is an unmet need to predict the risk and onset of severe inflammatory disease leading to poor clinical outcomes. In addition, very few mechanistic biomarkers are available to inform targeted treatment of severe (auto)-inflammatory conditions associated with COVID-19. Calprotectin, also known as S100A8/S100A9, MRP8/14 (Myeloid-Related Protein) or L1, is a heterodimer involved in neutrophil-related inflammatory processes. In COVID-19 patients, calprotectin levels were reported to be associated with poor clinical outcomes such as significantly reduced survival time, especially in patients with severe pulmonary disease. Areas covered: Pubmed was searched using the following keywords: Calprotectin + COVID19, S100A8/ A9 + COVID19, S100A8 + COVID-19, S100A9 + COVID-19, MRP8/14 + COVID19; L1 + COVID-19 between May 2020 and 8 March 2021. The results summarized in this review provide supporting evidence and propose future directions that define calprotectin as an important biomarker in COVID-19. Expert opinion: Calprotectin represents a promising serological biomarker for the risk assessment of COVID-19 patients.

show abstract

“…Patients that presented low plasma citrulline concentrations also showed higher systemic inflammation. Moreover, low citrulline and gastrointestinal symptoms were associated with more severe diseases [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

I-FABP is decreased in COVID-19 patients, independently of the prognosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is frequently associated with gastrointestinal manifestations. Herein we evaluated the interest in measuring the intestinal fatty acid-binding protein (I-FABP), a biomarker of intestinal injury, in COVID-19 patients. Methods Serum I-FABP was analyzed in 28 consecutive patients hospitalized for a PCR-confirmed COVID-19, in 24 hospitalized patients with non-COVID-19 pulmonary diseases, and 79 patients admitted to the emergency room for abdominal pain. Results I-FABP serum concentrations were significantly lower in patients with COVID-19, as compared to patients with non-COVID-19 pulmonary diseases [70.3 pg/mL (47–167.9) vs. 161.1 pg/mL (88.98–305.2), respectively, p = 0.008]. I-FABP concentrations in these two populations were significantly lower than in patients with abdominal pain without COVID-19 [344.8 pg/mL (268.9–579.6)]. I-FABP was neither associated with severity nor the duration of symptoms. I-FABP was correlated with polymorphonuclear cell counts. Conclusions In this pilot study, we observed a low I-FABP concentration in COVID-19 patients either with or without gastrointestinal symptoms, of which the pathophysiological mechanisms and clinical impact remain to be established. Further explorations on a larger cohort of patients will be needed to unravel the molecular mechanism of such observation, including the effects of malabsorption and/or abnormal lipid metabolism.

show abstract

Patients with COVID-19 present with low plasma citrulline concentrations that associate with systemic inflammation and gastrointestinal symptoms

Cited by 19 publications

References 6 publications

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Circulating Calprotectin as a Biomarker of COVID-19 Severity

I-FABP is decreased in COVID-19 patients, independently of the prognosis

Contact Info

Product

Resources

About